0000000000523540

AUTHOR

J. Homewood

showing 1 related works from this author

Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leuke…

2014

Item does not contain fulltext In chronic lymphocytic leukemia (CLL) medical progress is driven by clinical studies with relapse-free survival (RFS) as the primary endpoint. The randomized EBMT-Intergroup trial compared high-dose therapy and autologous stem cell transplantation (ASCT) to observation and demonstrated a substantial improvement of RFS without showing improved overall survival for the transplant arm. Here we report quality of life (QoL) information of the first 3 years following randomization from that study. The main objective was to assess the impact of treatment on QoL over time. Two secondary analyses were performed to further investigate the impact of ASCT and relapse on Q…

AdultMaleOncologymedicine.medical_specialtyTransplantation ConditioningRandomizationCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2][SDV]Life Sciences [q-bio]medicine.medical_treatmentChronic lymphocytic leukemiaHematopoietic stem cell transplantationTransplantation Autologous03 medical and health sciences0302 clinical medicineAutologous stem-cell transplantationQuality of lifeRecurrenceSurveys and QuestionnairesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansComputingMilieux_MISCELLANEOUSAgedbusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-Cellhumanities3. Good healthSurgeryTransplantation030220 oncology & carcinogenesisQuality of LifeFemaleTransplantation Conditioningbusiness030215 immunologyAmerican Journal of Hematology
researchProduct